Aducanumab: Appropriate Use Recommendations

por Cummings, J., Aisen, P., Apostolova, L.G., Atri, A., Salloway, S., Weiner, M.
Publicado 2021

Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheim...

por Kellar, D., Lockhart, S.N., Aisen, P., Raman, R., Rissman, R.A., Brewer, J., Craft, S.
Publicado 2021

Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force

por Aisen, P. S., Bateman, R. J., Carrillo, M., Doody, R., Johnson, K., Sims, J. R., Sperling, R., Vellas, B.
Publicado 2021

Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials

por Langford, O., Raman, R., Sperling, R.A., Cummings, J., Sun, C.-K., Jimenez-Maggiora, G., Aisen, P.S., Donohue, M.C.
Publicado 2020

The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program

por Berkness, Tyler, Carrillo, M. C., Sperling, R., Petersen, R., Aisen, P., Flournoy, C., Snyder, H., Raman, R., Grill, J. D.
Publicado 2021

Aducanumab: Appropriate Use Recommendations Update

por Cummings, J., Rabinovici, G.D., Atri, A., Aisen, P., Apostolova, L.G., Hendrix, S., Sabbagh, M., Selkoe, D., Weiner, M., Salloway, S.
Publicado 2022

TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology

por Jimenez-Maggiora, G.A., Bruschi, S., Raman, R., Langford, O., Donohue, M., Rafii, M.S., Sperling, R.A., Cummings, J.L., Aisen, P.S.
Publicado 2020

Alzheimer’s Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer’s Clinical Trial Consortium Sites

por Rhodus, Elizabeth K., Aisen, P., Grill, J. D., Rentz, D. M., Petersen, R. C., Sperling, R. A., Salloway, S. P., Pierce, D., Raman, R.
Publicado 2022

The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview

por Aisen, P.S., Sperling, R.A., Cummings, J., Donohue, M.C., Langford, O., Jimenez-Maggiora, G.A., Rissman, R.A., Rafii, M.S., Walter, S., Clanton, T., Raman, R.
Publicado 2020

The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years

por Walter, S., Langford, O.G., Clanton, T.B., Jimenez-Maggiora, G.A., Raman, R., Rafii, M.S., Shaffer, E.J., Sperling, R.A., Cummings, J.L., Aisen, P.S.
Publicado 2020

Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report

por Raman, Rema, Aisen, P., Carillo, M. C., Detke, M., Grill, J. D., Okonkwo, O. C., Rivera-Mindt, M., Sabbagh, M., Vellas, B., Weiner, M., Sperling, R.
Publicado 2022

Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)

por Walter, S., Clanton, T.B., Langford, O.G., Rafii, M.S., Shaffer, E.J., Grill, J.D., Jimenez-Maggiora, G.A., Sperling, R.A., Cummings, J.L., Aisen, P.S.
Publicado 2020

Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment

por Hu, X, Pickering, E H, Hall, S K, Naik, S, Liu, Y C, Soares, H, Katz, E, Paciga, S A, Liu, W, Aisen, P S, Bales, K R, Samad, T A, John, S L
Publicado 2011

Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report

por Gauthier, Serge, Aisen, P. S., Cummings, J., Detke, M. J., Longo, F. M., Raman, R., Sabbagh, M., Schneider, L., Tanzi, R., Tariot, P., Weiner, M., Touchon, J., Vellas, B.
Publicado 2020

Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force

por Kaye, Jeffrey, Aisen, P., Amariglio, R., Au, R., Ballard, C., Carrillo, M., Fillit, H., Iwatsubo, T., Jimenez-Maggiora, G., Lovestone, S., Natanegara, F., Papp, K., Soto, M. E., Weiner, M., Vellas, B.
Publicado 2021

The Computerized Cognitive Composite (C3) in A4, an Alzheimer’s Disease Secondary Prevention Trial

por Papp, K.V., Rentz, D.M., Maruff, P., Sun, C.-K., Raman, R., Donohue, M.C., Schembri, A., Stark, C., Yassa, M.A., Wessels, A.M., Yaari, R., Holdridge, K.C., Aisen, P.S., Sperling, R.A.
Publicado 2021

Structural basis for iron piracy by pathogenic Neisseria

por Noinaj, N., Easley, N.C., Oke, M., Mizuno, N., Gumbart, J., Boura, E., Steere, A.N., Zak, O., Aisen, P., Tajkhorshid, E., Evans, R.W., Gorringe, A.R., Mason, A.B., Steven, A.C., Buchanan, S.K.
Publicado 2012

How Will Aducanumab Approval Impact AD Research?

por Weiner, Michael W., Aisen, P. S., Beckett, L. A., Green, R. C., Jagust, W., Morris, J. C., Okonkwo, O., Perrin, R. J., Petersen, R. C., Rivera Mindt, M., Saykin, A. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q.
Publicado 2021

Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data

por Amariglio, R.E., Sikkes, S.A.M., Marshall, G.A., Buckley, R.F., Gatchel, J.R., Johnson, K.A., Rentz, D.M., Donohue, M.C., Raman, R., Sun, C.-K., Yaari, R., Holdridge, K.C., Sims, J.R., Grill, J.D., Aisen, P.S., Sperling, R.A.
Publicado 2021

Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force

por Angioni, D., Delrieu, J., Hansson, O., Fillit, H., Aisen, P., Cummings, J., Sims, J.R., Braunstein, J.B., Sabbagh, M., Bittner, T., Pontecorvo, M., Bozeat, S., Dage, J.L., Largent, E., Mattke, S., Correa, O., Robledo, L.M. Gutierrez, Baldivieso, V., Willis, D.R., Atri, A., Bateman, R.J., Ousset, P-J., Vellas, B., Weiner, M.
Publicado 2022